Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.255,33 -18,72 (-0,05%) EUR/USD
1,0718 0,0000 (-0,00%) Bitcoin EUR
53.588,85 -2.596,53 (-4,62%) CMC Crypto 200
1.260,87 -78,20 (-5,85%)
Marker Therapeutics, Inc. (MRKR)
| Chiusura precedente | 4,0500 |
| Aperto | 4,0500 |
| Denaro | 2,9900 x 200 |
| Lettera | 5,2400 x 200 |
| Min-Max giorno | 4,0500 - 4,2700 |
| Intervallo di 52 settimane | 1,1600 - 9,6800 |
| Volume | |
| Media Volume | 18.296 |
| Capitalizzazione | 36,591M |
| Beta (5 anni mensile) | 1,54 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,5900 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,50 |
GlobeNewswireMarker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Pala
- GlobeNewswire
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead Marker’s restructuring efforts and guide clinical advancement of Marker’s multiTAA-specific T cell technology Announced encouraging non-clinical data from MT-401 program demonstrating increased anti-tumor activity against an ac
- GlobeNewswire
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced non-clinical data of its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program
